P4350 - Efficacy of Guselkumab vs Placebo In Crohn’s Disease Based on Prior Response/Exposure to Biologic Therapy: Results of the GALAXI 2 and 3 Phase 3 Studies
Icahn School of Medicine at Mount Sinai New York, NY
Bruce E.. Sands, MD, FACG1, Geert R. D'Haens, MD, PhD2, Silvio Danese, MD, PhD3, Tadakazu Hisamatsu, MD, PhD4, Walter Reinisch, MD, PhD5, Natalie A. Terry, MD, PhD6, Leonardo Salese, MD7, Rian Van Rampelbergh, MD8, Zijiang Yang, PhD9, Jewel Johanns, PhD6, George DuVall, MD10, Niazy Abu Farsakh, MBBCh, MRCP11, Remo Panaccione, MD12 1Icahn School of Medicine at Mount Sinai, New York, NY; 2Amsterdam University Medical Center, Amsterdam, Limburg, Netherlands; 3Humanitas Clinical and Research Center - IRCCS, Rozzano and Humanitas University, Pieve Emanuele, Milan, Lombardia, Italy; 4Kyorin University School of Medicine, Tokyo, Tokyo, Japan; 5Medical University of Vienna, Vienna, Wien, Austria; 6Janssen Research & Development, LLC, Spring House, PA; 7Janssen Research & Development, LLC, Horsham, PA; 8Janssen Research and Development, Antwerp, Antwerpen, Belgium; 9Janssen Research and Development, Horsham, PA; 10Tyler Research Institute, LLC, Tyler, TX; 11King Abdullah University Hospital, Irbid, Irbid, Jordan; 12University of Calgary, Calgary, AB, Canada
Introduction: GALAXI 2 & 3 are identically designed 48-week, randomized, double-blind, double-dummy, placebo (PBO)- and active-comparator, treat-through registrational trials assessing the efficacy and safety of IV induction and SC maintenance therapy with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) with moderately to severely active Crohn’s disease (CD). Primary results of each study were previously reported; here we explore the impact of biologic therapy exposure on efficacy outcomes with GUS compared to PBO in the pooled GALAXI 2 & 3 dataset.
Methods: Pts with inadequate response or intolerance to conventional therapy or biologic therapy (BIO-ir), active CD (CDAI 220–450 + mean daily SF >3 or AP >1), and SES-CD≥6 (≥4 for isolated ileal disease) were randomly assigned 2:2:2:1 at week (Wk) 0 to GUS 200mg IV q4w (x3)→100mg SC q8w, GUS 200mg IV q4w (x3)→200mg SC q4w, UST IV→SC, or PBO. In each trial, the composite co-primary endpoints were 1) clinical response at Wk12 and clinical remission at Wk48, and 2) clinical response at Wk12 and endoscopic response at Wk48, comparing each GUS regimen to PBO. Major secondary endpoints included clinical remission at Wk12 and endoscopic response at Wk12. Analyses of BIO-ir and BIO-naïve subgroups in the individual trials were prespecified; pooled analyses were performed post hoc.
Results: In the pooled dataset, 52% (378/730) of pts randomized to PBO or GUS had a prior history of BIO-ir and 42% (305/730) were BIO-naïve (6% [47/730] had prior exposure to biologics but no documented failure). At Wk12, GUS achieved higher rates of clinical remission and endoscopic response compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups (Table). For the composite co-primary endpoints, both GUS regimens also achieved higher rates of 1) clinical response at Wk12 and clinical remission at Wk48 and 2) clinical response at Wk12 and endoscopic response at Wk48 compared to PBO in the overall population and BIO-ir and BIO-naïve subgroups (Figure).
Discussion: In pooled analyses of the double-blind GALAXI 2 & 3 trials, GUS was efficacious versus PBO in pts with CD regardless of prior biologic therapy exposure in both short-term (Wk12) endpoints and long-term (Wk12 and Wk48) composite endpoints.
Figure: Figure. Efficacy of guselkumab (GUS) and placebo (PBO) for long-term (Wk 12 and Wk 48) clinical and endoscopic endpoints in all participants and BIO-ir and BIO-naïve subgroups in the pooled GALAXI 2 & 3 dataset
Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
Bruce E.. Sands, MD, FACG1, Geert R. D'Haens, MD, PhD2, Silvio Danese, MD, PhD3, Tadakazu Hisamatsu, MD, PhD4, Walter Reinisch, MD, PhD5, Natalie A. Terry, MD, PhD6, Leonardo Salese, MD7, Rian Van Rampelbergh, MD8, Zijiang Yang, PhD9, Jewel Johanns, PhD6, George DuVall, MD10, Niazy Abu Farsakh, MBBCh, MRCP11, Remo Panaccione, MD12. P4350 - Efficacy of Guselkumab vs Placebo In Crohn’s Disease Based on Prior Response/Exposure to Biologic Therapy: Results of the GALAXI 2 and 3 Phase 3 Studies, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.